MediWound (MDWD): Strong Industry, Solid Earnings Estimate Revisions
- MediWound (MDWD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 01/09/2024
|
Does MediWound (MDWD) Have the Potential to Rally 223.05% as Wall Street Analysts Expect?
- The consensus price target hints at a 223.1% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 11/27/2023
|
MediWound to Report Third Quarter 2023 Financial Results
- Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time
- 11/14/2023
|
MediWound (MDWD) Surges 18.2%: Is This an Indication of Further Gains?
- MediWound (MDWD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 09/29/2023
|
MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference
- YAVNE, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming H.C. Wainwright 25th Annual Global Investment Conference. The conference will take place in New York City and virtually from September 11-13, 2023.
- 09/05/2023
|
MediWound (MDWD) Q2 Earnings and Revenues Beat Estimates
- MediWound (MDWD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.41 per share. This compares to loss of $0.91 per share a year ago.
- 08/15/2023
|
MediWound to Report Second Quarter 2023 Financial Results
- Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time
- 08/07/2023
|
3 Micro-Cap Stocks to Buy for Multibagger Returns
- Micro-cap stocks, by definition, are stocks of companies that trade at a valuation range of $50 to $300 million. It goes without saying that investing in micro-cap stocks is a high-risk game.
- 07/11/2023
|
MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023
- YAVNE, Israel, June 14, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming Healthcare Virtual Conference Part II, organized by Maxim Group LLC and hosted by M-Vest. The conference will take place online from June 20 to June 22, 2023.
- 06/14/2023
|
MediWound: With Expenses Covered, Growth Is Within Reach
- MediWound, a company developing medical solutions for skin and burn conditions, is set to begin US distribution of its burn solution NexoBrid in Q3 2023. With a cash pile of over $57 million, the company will be able to cover operating expenses and then some for the next 2-3 years as they ramp up production. Despite past share price underperformance, I remain cautiously bullish on the company's long term prospects and believe they are worth around double their current valuation.
- 05/31/2023
|
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
- MediWound (MDWD) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.84 per share a year ago.
- 05/30/2023
|
MediWound to Report First Quarter 2023 Financial Results
- Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time
- 05/12/2023
|
MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023
- Data to be highlighted in oral and poster presentations YAVNE, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic solutions for tissue repair, today announced the Company will present updated clinical data from the three EscharEx® Phase 2 trials at the 2023 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society taking place in National Harbor, Maryland on April 26-30, 2023.
- 04/26/2023
|
MediWound Ltd. (MDWD) Q4 2022 Earnings Call Transcript
- MediWound Ltd. (NASDAQ:MDWD ) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Monique Kosse - LifeSci Advisors, IR Ofer Gonen - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call Participants Josh Jennings - TD Cowen Francois Brisebois - Oppenheimer Swayampakula Ramakanth - H.C.
- 03/16/2023
|
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
- MediWound (MDWD) delivered earnings and revenue surprises of -521.05% and 56.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/16/2023
|
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
- Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time
- 03/02/2023
|
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
- YAVNE, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced management will present at two upcoming investor conferences in March. Details for each is as follows:
- 02/23/2023
|
MediWound Ltd. (MDWD) Q3 2022 Earnings Call Transcript
- MediWound Ltd. (NASDAQ:MDWD ) Q3 2022 Earnings Conference Call November 15, 2022 8:30 AM ET Company Participants Monique Kosse - MD, LifeSci Advisors Ofer Gonen - CEO Boaz Gur-Lavie - CFO Conference Call Participants Josh Jennings - Cowen Francois Brisebois - Oppenheimer Swayampakula Ramakanth - H.C.
- 11/15/2022
|
MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates
- MediWound (MDWD) delivered earnings and revenue surprises of -30% and 24.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/15/2022
|
MediWound Ltd. (MDWD) CEO Ofer Gonen on Q2 2022 Results - Earnings Call Transcript
- MediWound Ltd. (NASDAQ:MDWD ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Monique Kosse - Investor Relations Ofer Gonen - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call Participants Bryan Bergin - Cowen Ryan Zimmerman - BTIG Arthur He - H.C.
- 08/10/2022
|
MediWound Schedules Second Quarter 2022 Financial Results
- Conference Call and Webcast Scheduled for Tuesday, August 9, 2022 at 8:30 AM ET Conference Call and Webcast Scheduled for Tuesday, August 9, 2022 at 8:30 AM ET
- 08/01/2022
|
MediWound Ltd. (MDWD) CEO Sharon Malka on Q1 2022 Results - Earnings Call Transcript
- MediWound Ltd. (NASDAQ:MDWD ) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET Company Participants Monique Kosse - IR Sharon Malka - CEO Boaz Gur-Lavie - Chief Financial Officer Ofer Gonen - Board Member Lior Rosenberg - Chief Medical Officer Cyaandi R.
- 05/17/2022
|
MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
- MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 1.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/17/2022
|
MediWound Posts Promising EscharEx Data For Chronic Wounds
- MediWound Ltd (NASDAQ: MDWD) has announced results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers (VLUs). The study met its primary and secondary endpoints and wound closure safety measurements.
- 05/12/2022
|
MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022
- YAVNE, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the first quarter ended March 31, 2022 on Tuesday, May 17, 2022.
- 05/10/2022
|
MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022
- Results Highlight the Safety and Efficacy in Hard-to-Heal Wounds
- 03/29/2022
|
MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2021 Results - Earnings Call Transcript
- MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2021 Results - Earnings Call Transcript
- 03/17/2022
|
MediWound (MDWD) Reports Q4 Loss, Misses Revenue Estimates
- MediWound (MDWD) delivered earnings and revenue surprises of 6.25% and 2.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/17/2022
|
MediWound to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022
- YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2021 on Thursday, March 17 2022.
- 03/10/2022
|
MediWound to Present at Upcoming Investor Conferences in February
- YAVNE, Israel, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management would present at two upcoming investor conferences in February. Details for each is as follows:
- 02/14/2022
|
MediWound's EscharEx Mid-Stage Trial Meets Primary Goal In Venous Leg Ulcers
- MediWound Ltd (NASDAQ: MDWD) has posted topline results from its U.S. Phase 2 study of EscharEx for the debridement (removal of dead or infected skin tissue for wound healing) of venous leg ulcers (VLUs). The study randomized 120 patients, of which 119 patients were treated by either EscharEx (n=46), a gel vehicle (n=43), or a non-surgical standard-of-care consisting of either enzymatic or autolytic debridement (n=30).
- 01/24/2022
|
MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2021 Results - Earnings Call Transcript
- MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2021 Results - Earnings Call Transcript
- 11/16/2021
|
MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates
- MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and 13.79%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/16/2021
|
Earnings Preview For MediWound
- MediWound (NASDAQ:MDWD) is set to give its latest quarterly earnings report on Tuesday, 2021-11-16. Here's what investors need to know before the announcement.
- 11/15/2021
|
MediWound Announces Peer-Reviewed Publication of EscharEx In-Vivo Head-to-Head Comparator Study in the Journal of Wound Care
- EscharEx Treatment Demonstrated Superior Efficacy in Debridement of Eschar EscharEx Treatment Demonstrated Superior Efficacy in Debridement of Eschar
- 10/04/2021
|
MediWound to Present at Upcoming Investor Conferences
- YAVNE, Israel, Sept. 03, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management will present at the following investor conferences during the month of September 2021.
- 09/03/2021
|
Mediwound Ltd (MDWD) CEO Sharon Malka on Q2 2021 Results - Earnings Call Transcript
- Mediwound Ltd (MDWD) CEO Sharon Malka on Q2 2021 Results - Earnings Call Transcript
- 08/10/2021
|
MediWound (MDWD) Reports Q2 Loss, Tops Revenue Estimates
- MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 6.36%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/10/2021
|
MediWound Reports Second Quarter Financial Results
- Second Quarter Revenues of $6.1 Million - Increase of 50% Year-over-Year
- 08/10/2021
|
MediWound to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 10, 2021
- YAVNE, Israel, Aug. 02, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the second quarter ended June 30, 2021 at 7:00 am Eastern Time on Tuesday, August 10, 2021.
- 08/02/2021
|
MediWound: Disappointing Thus Far But Still A Strong Buy
- MediWound: Disappointing Thus Far But Still A Strong Buy
- 07/30/2021
|
MediWound: Adjusting My Strategy After NexoBrid CRL
- MediWound: Adjusting My Strategy After NexoBrid CRL
- 07/28/2021
|
MediWound Starts Testing MW005 In Two Mid-Stage Trials In Patients With Non-Melanoma Skin Cancer
- MediWound Ltd (NASDAQ: MDWD) has initiated a Phase 1/2 study of MW005 to treat low-risk Basal Cell Carcinoma (BCC). In parallel, an investigator-initiated Phase 2 trial of MW005 in non-melanoma skin cancers is being conducted at the Soroka Medical Center in Israel.
- 07/26/2021
|
MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
- Data Expected End of 2021
- 07/26/2021
|
MediWound's NexoBrid Shows Significant Beneficial Impact On Pediatric Burn Patients
- MediWound Ltd (NASDAQ: MDWD) has announced topline results from Phase 3 pediatric study with NexoBrid to treat severe thermal burns. The 145-subject study met its three primary endpoints.
- 07/20/2021
|
MDWD Stock Increases Over 15% Pre-Market: Why It Happened
- The stock price of Mediwound Ltd (NASDAQ: MDWD) increased by over 15% pre-market. This is why it happened.
- 07/20/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD
- NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. ("MediWound" or the "Company") (NASDAQ: MDWD).
- 07/18/2021
|
MediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the Online Wound Repair and Regeneration Journal
- Study Findings D emonstrate S trong R esults in Debriding V enous L eg U lcers and D iabetic F oot U lcers
- 07/09/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD
- New York, New York--(Newsfile Corp. - July 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. ("MediWound" or the "Company") (NASDAQ: MDWD). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether MediWound and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 07/05/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD
- NEW YORK, June 29, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. ("MediWound" or the "Company") (NASDAQ: MDWD).
- 06/29/2021
|
Why Shares Of MediWound And Vericel Fell On Tuesday
- Shares of MediWound (NASDAQ: MDWD) and its development partner, Vericel Corporation (NASDAQ: VCEL), are trading lower after MediWound received a Complete Response Letter from the FDA for its NexoBrid Biologics License Application. The FDA identified issues related to the Chemistry, Manufacturing, and Controls (CMC) section of the application and requested that MediWound provide additional CMC information.
- 06/29/2021
|
FDA Strikes Off MediWound - Vericel's NexoBrid Biologics License Application; Stocks Drop
- Vericel Corporation's (NASDAQ:VCEL) development partner, MediWound Ltd (NASDAQ:MDWD), received a complete response letter from FDA regarding the NexoBrid application seeking approval for eschar removal in adults with deep partial-thickness or full-thickness burns. The FDA identified issues related to the Chemistry, Manufacturing, and Controls (CMC) section of the application and requested that MediWound provide additional CMC information.
- 06/29/2021
|
MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application
- Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy
- 06/29/2021
|
Best Penny Stocks To Buy Now? 7 To Watch This Week
- What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?
- 06/20/2021
|
MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study
- Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021 Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021
- 06/09/2021
|
MediWound Ltd (MDWD) CEO Sharon Malka on Q1 2021 Results - Earnings Call Transcript
- MediWound Ltd (MDWD) CEO Sharon Malka on Q1 2021 Results - Earnings Call Transcript
- 05/08/2021
|
MediWound: Managing A Position Ahead Of NexoBrid's PDUFA
- MediWound is preparing for NexoBrid's PDUFA date that is scheduled in June of this year. If approved, NexoBrid will be entering a $200M TAM with numerous benefits over the standard-of-care.
- 05/02/2021
|
Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for
- MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/28/2021
|
MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021
- YAVNE, Israel, April 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the first quarter ended March 31, 2021 at 7:00 am Eastern Time on Wednesday, May 5, 2021.
- 04/26/2021
|
MediWound Hosting Analyst Day Webinar on EscharEx – Enzymatic Debridement Agent for Chronic Wounds
- Webinar To Be Held on Tuesday, March 30th at 10am Eastern Time Webinar To Be Held on Tuesday, March 30th at 10am Eastern Time
- 03/24/2021
|
MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2020 Results - Earnings Call Transcript
- MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2020 Results - Earnings Call Transcript
- 02/28/2021
|
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
- MediWound (MDWD) delivered earnings and revenue surprises of 45.45% and 19.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 02/25/2021
|
MediWound Launches Clinical Development Program for Treatment of Non-Melanoma Skin Cancer
- Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin Second Quarter 2021, with Data Expected by the End of 2021
- 02/22/2021
|
MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/18/2021
|
MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021
- YAVNE, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2020 at 7:00 am Eastern Time on Thursday, February 25, 2021.
- 02/16/2021
|
MediWound to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- YAVNE, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka, Chief Executive Officer, will participate in a fireside chat during the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which is being held February 17-19, 2021.
- 02/10/2021
|
7 Penny Stocks That Actually Have Buy Ratings
- Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.
- 02/03/2021
|
MediWound Provides Progress Update on Its EscharEx Clinical Development Program
- Phase 2 Adaptive Design Study Sample Size Reduced to 120 Patients
- 01/11/2021
|
MediWound to Participate in Upcoming Investor Conferences in January
- YAVNE, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it will participate in the forthcoming LifeSci Partners 10th Annual Corporate Access Event and the H.C. Wainwright BioConnect 2021 Conference. Both conferences will take place virtually.
- 01/05/2021
|
MediWound: A Collectable Investment Worthy Of A Long-Term Hold
- MediWound recently reported an encouraging Q3 with a beat on EPS and revenue. It looks as if the company is easily weathering the pandemic with support from BARDA purchases. I have already established a speculative position ahead of a potential NexoBrid approval. Now, I am looking to stick my MDWD in the back of my sock drawer.
- 12/22/2020
|
Successful Completion of In-Vivo Head-to-Head Comparator Study of EscharEx versus a Commercial Enzymatic Debridement Agent
- Data to be Published in a Peer-Reviewed Journal in First Half 2021 Data to be Published in a Peer-Reviewed Journal in First Half 2021
- 12/21/2020
|
MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group
- YAVNE, Israel, Dec. 14, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has further expanded its NexoBrid® global presence and entered the Middle Eastern markets with the signing of a distribution agreement granting Ghassan Aboud Group (GAG), an international conglomerate based in the United Arab Emirates (UAE), an exclusive right to market and distribute NexoBrid in UAE for the treatment of severe burns. Commercialization of NexoBrid in the UAE will commence upon securing regulatory approval, which is expected within a year.
- 12/14/2020
|
MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2020 Results - Earnings Call Transcript
- MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2020 Results - Earnings Call Transcript
- 11/10/2020
|
MediWound: Q3 Earnings Insights
- Shares of MediWound (NASDAQ:MDWD) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share rose 36.36% over the past year to ($0.07), which beat the estimate of ($0.10).
- 11/10/2020
|
MediWound Reports Third Quarter 2020 Financial Results
- Total Third Quarter R evenues of $6.6 Million Increased 29 % Y ear-over- Y ear
- 11/10/2020
|
MediWound to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 10, 2020
- YAVNE, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the third quarter ended September 30, 2020 at 7:00 am Eastern Time on Tuesday, November 10, 2020.
- 11/02/2020
|
MediWound Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric Study
- Top-line Data is Expected in the Second Half of 2021 Top-line Data is Expected in the Second Half of 2021
- 10/28/2020
|
MediWound: An Underfollowed Opportunity At A Discount
- MediWound has popped up on my scanner multiple times over the past few years but the conditions never lined up for me to establish a position.
- 09/08/2020
|
MediWound (MDWD) Reports Q2 Loss, Lags Revenue Estimates
- MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and -15.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/06/2020
|
MediWound Reports Second Quarter 2020 Financial Results and Provides Corporate Update
- Submitted Biological License Application to the FDA for NexoBrid EscharEx U.S. Phase 2 Study Resumed Patient ScreeningYAVNE, Israel, Aug. 06, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced financial results for the second quarter ended June 30, 2020 and provided business and financial updates related to the COVID-19 pandemic. Second Quarter Business and Financial Highlights: * Revenues for the second quarter of 2020 were $4.0 million, compared with $20.7 million for the second quarter of 2019, which included the upfront payment of $17.5 million from the Vericel licensing agreement * The Company had $24.4 million in cash and short-term investments as of June 30, 2020, compared with $29.5 million as of December 31, 2019 * Resumed patient screening and randomization in U.S. EscharEx® phase 2 adaptive design study for the treatment of venous leg ulcers (“VLU’s”); Interim assessment is anticipated in the first half of 2021 * Submitted Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for NexoBrid® for the treatment of severe thermal burns in adults * Instituted a series of measures to address challenges associated with the COVID-19 pandemic, while maintaining workforce and operational capacity and flexibility“We are pleased to have submitted the BLA for NexoBrid on schedule despite the disruptions of the COVID-19 pandemic. This submission is a major milestone in our long-term partnership with BARDA, and we are actively preparing for the commercial launch with our partner, Vericel, upon approval,” said Sharon Malka, Chief Executive Officer of MediWound. “In addition, we are actively recruiting and enrolling patients in our U.S. EscharEx phase 2 study, and we are encouraged to see progress in moving this trial forward.”Mr. Malka concluded, “In recent months, humanity is facing tremendous challenges with a great deal of uncertainty. We are privileged to be among those tasked with improving patients’ quality of care and impacting their lives. Our solid balance sheet continues to support our growth as we execute on our strategic plans, and we are optimistic that we will continue to successfully strengthen our Company.”Corporate UpdateMediWound has implemented several measures to safeguard the health and well-being of its employees, their families, and healthcare providers. The Company has reduced expenses to minimize impact to operations while ensuring full compliance with all necessary regulations. Management continues to assess the impact of the pandemic, the potential implications to business continuity, and necessary remedies and will adjust accordingly to the challenges created by any directives from regulatory authorities.The Company continues to manufacture and supply NexoBrid to patients with severe burn injuries, including manufacturing NexoBrid and building an emergency stockpile for the U.S. Biomedical Advanced Research and Development Authority (BARDA), while the first delivery to BARDA is planned in the third quarter of 2020. The Company maintains a significant safety stock of all key raw materials and NexoBrid inventory to meet expected demand over the next several quarters. At this time, the Company does not expect any disruptions to its manufacturing operations and global supply chain. The Company submitted a BLA to the U.S. FDA seeking the approval of NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and full-thickness thermal burns. The BLA submission is based on multiple preclinical and clinical studies including the pivotal Phase 3 U.S. clinical study (DETECT) of NexoBrid in adult patients with severe thermal burns. Vericel Corporation (NASDAQ: VCEL) holds an exclusive license for North American commercial rights of NexoBrid. MediWound is eligible to receive a $7.5 million milestone payment from Vericel upon BLA approval. On the clinical front, the Company has resumed new patients’ screening and randomization in its U.S. EscharEx phase 2 adaptive design study for the treatment of VLU’s and expects to achieve the pre-defined interim assessment in the first half of 2021. In addition, enrollment in the NexoBrid expanded access (NEXT) program continues with enhanced safety measures, such as remote visits and virtual tools.The Company had $24.4 million in cash and short-term investments as of June 30, 2020, compared with $29.5 million as of December 31, 2019, with no debt. The Company reiterates its expectations of cash use for operating activities in 2020 to be in the range of $8 to $10 million. At this time, the Company cannot predict the extent or duration of the impact of the COVID-19 outbreak on its ongoing financial and operational results.Second Quarter Financial ResultsRevenues for the second quarter of 2020 were $4.0 million, compared with $20.7 million for the second quarter of 2019, which included the upfront payment of $17.5 million from the Vericel licensing agreement. Revenues from product in the second quarter of 2020 were $1.1 million, reflecting an increase of 17% in comparison to the second quarter of 2019, excluding the one-time upfront payment.Gross profit for the second quarter of 2020 was $1.2 million, compared to a gross profit of $17.5 million for the second quarter of 2019, which included $16.8 million from the Vericel licensing agreement. Research and development expenses for the second quarter of 2020, net of participations, were $1.6 million, compared with $0.4 million for the second quarter of 2019. The increase was primarily due to decrease of participation by BARDA and Israeli Innovation Authority (IIA). Selling, general and administrative expenses for the second quarter of 2020 were $2.3 million, in line with the second quarter of 2019.Operating loss for the second quarter of 2020 was $2.7 million, compared with an operating profit of $13.9 million in the second quarter of 2019, which included the upfront payment of $17.5 million from the Vericel licensing agreement, net of royalty payment of $0.7 million and $0.8 million of other expenses. The Company posted a net loss of $3.1 million, or $0.11 per share, for the second quarter of 2020 compared with a net profit of $12.7 million, or $0.47 per share, for the second quarter of 2019, which included the $17.5 million upfront license payment, net of royalty payment of $0.7 million and $0.8 million of other expenses. Excluding the upfront license payment net of deal related costs, net loss for the second quarter of 2019 was $3.3 million, or $0.12 per share.Adjusted EBITDA, as defined below, for the second quarter of 2020 was a loss of $2.1 million, compared with a profit of $15.4 million for the second quarter of 2019, which included the upfront payment of $17.5 million from the Vericel licensing agreement, net of royalty payment of $0.7 million. Year-to-Date 2020 Financial ResultsRevenues for the first half of 2020 were $8.5 million compared with $21.2 million in the first half of 2019, which included the $17.5 million upfront payment from the Vericel licensing agreement for NexoBrid.The Company’s net loss for the first half of 2020 was $5.6 million or $0.20 per share compared with net profit of $8.6 million or $0.32 per share for the first half of 2019, which included the $17.5 million upfront license payment, net of royalty payment of $0.7 million and $0.9 million of other expenses. Excluding the upfront license payment net of deal related costs, net loss for the first half of 2019 was $7.3 million, or $0.27 per share.Adjusted EBITDA, for the first half of 2020, was a loss of $3.9 million, compared with a profit of $12.4 million for the first half of 2019, which included the upfront payment of $17.5 million from the Vericel licensing agreement, net of royalty payment of $0.7 million. Conference CallMediWound management will host a conference call for investors today, Thursday, August 6, 2020 beginning at 8:30 a.m. Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 877-602-7189 (in the U.S.) 1809 315 362 (Israel), or 678-894-3057 (outside the U.S. & Israel) and entering passcode 3176168. The call also will be webcast live on the Company’s website at http://ir.mediwound.com/events-and-presentations.A replay of the call will be accessible two hours after its completion through August 27, 2020 by dialing 855-859-2056 (in the U.S.) or 404-537-3406 (outside the U.S.) and entering passcode 3176168. The call will also be archived on the Company website for 90 days at www.mediwound.com.About MediWound Ltd.MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, non-surgically and rapidly removes burn eschar without harming viable tissue. The product has received marketing authorization from the European Medicines Agency as well as the Israeli, Argentinian, South Korean, Russian and Peruvian Ministries of Health. MediWound’s second innovative product, EscharEx® is a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds using the same proteolytic enzyme technology as NexoBrid. In two Phase 2 studies, EscharEx has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications. For more information, please visit www.mediwound.com.
- 08/06/2020
|
Should MediWound (NASDAQ:MDWD) Be Disappointed With Their 52% Profit?
- The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...
- 07/31/2020
|
MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/30/2020
|
MediWound to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020
- YAVNE, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the second quarter ended June 30, 2020 at 7:00 am Eastern Time on Thursday, August 6, 2020. Following the release, MediWound's management will host a conference call and live webcast on Thursday, August 6, 2020 at 8:30 am Eastern Time to discuss the financial results and to answer questions. Dial-in and call details are as follows:Conference Call & Webcast Details Toll-Free:877-602-7189 Israel Toll-Free:1 809 315 362 International:678-894-3057 Conference ID:3176168 Webcast:https://edge.media-server.com/mmc/p/jt3zx63y To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay for 90 days in the Investors section of the MediWound website.About MediWound Ltd. MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, non-surgically and rapidly removes burn eschar without harming viable tissue. The product has received marketing authorization from the European Medicines Agency as well as the Israeli, Argentinian, South Korean, Russian and Peruvian Ministries of Health. MediWound’s second innovative product, EscharEx® is a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds using the same proteolytic enzyme technology as NexoBrid. In two Phase 2 studies, EscharEx has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications. For more information, please visit www.mediwound.com.Contacts: Boaz Gur-Lavie Jeremy Feffer Chief Financial OfficerManaging Director MediWound Ltd.LifeSci Advisors, LLC ir@mediwound.com jeremy@LifeSciAdvisors.com
- 07/28/2020
|
MediWound (MDWD) Jumps: Stock Rises 9.4%
- MediWound (MDWD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
- 07/14/2020
|
MediWound Announces Submission of Biologics License Application to the U.S. FDA for NexoBrid for the Treatment of Severe Thermal Burns
- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn and wound management, today announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking the approval of NexoBrid® for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. The BLA submission includes a comprehensive set of manufacturing data, multiple preclinical and clinical studies including the pivotal U.S. Phase 3 (DETECT) study of NexoBrid in adult patients with deep partial and full-thickness thermal burns up to 30% of total body surface area.
- 06/30/2020
|
Zacks.com featured highlights include: MediWound, Issuer Direct, BWX Technologies and Teekay Tankers
- Zacks.com featured highlights include: MediWound, Issuer Direct, BWX Technologies and Teekay Tankers
- 05/27/2020
|
4 Profitable Stocks to Boost Returns Using Net Income Ratio
- Investors always look for companies with a high level of profitability regardless of the present market condition.
- 05/26/2020
|
MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
- MediWound (MDWD) delivered earnings and revenue surprises of 35.71% and 4.42%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/20/2020
|
MediWound shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.
|
30 Stocks Moving in Wednesday's Pre-Market Session
|
Recap: MediWound Q1 Earnings
- Shares of MediWound (NASDAQ:MDWD) moved higher by 6% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share rose 40.00% over the past year to ($0.09), which beat the estimate of ($0.14).Revenue of $4,438,000 up by 862.69% year over year, which beat the estimate of $4,050,000.Outlook MediWound hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: May 20, 2020View more earnings on MDWDTime: 08:30 AMET Webcast URL: https://mediwound.gcs-web.com/events-and-presentationsRecent Stock Performance 52-week high: $4.6552-week low: $1.44Price action over last quarter: down 13.33%Company Overview MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. Its first biopharmaceutical product, NexoBrid removes dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. NexoBrid is currently in clinical development in North America and is in the process of preparing its Biologics License Application. The company derives its revenue from United States.See more from Benzinga * McKesson: Q4 Earnings Insights * Recap: Lowe's Companies Q1 Earnings * ShiftPixy: P/E Ratio Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/20/2020
|
MediWound Q1 EPS $(0.090) Beats $(0.140) Estimate, Sales $4.400M Beat $4.050M Estimate
|
MediWound Reports First Quarter 2020 Financial Results and Provides Corporate Update
- YAVNE, Israel, May 20, 2020 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs.
- 05/20/2020
|
MediWound Ltd. to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / May 20, 2020 / MediWound Ltd. (NASDAQ:MDWD) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 20, 2020 at 8:30 AM Eastern ...
- 05/20/2020
|
The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 19)
ADC Therapeutics SA (NYSE:...
- 05/20/2020
|
The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows
- Biotech stocks had another up week, with the American Society of Gene & Stem Cell Therapy virtual conference presentations and the ASCO abstracts made available online ...
- 05/17/2020
|
MediWound to Report First Quarter 2020 Financial Results and Host a Conference Call and Webcast on May 20, 2020
- YAVNE, Israel, May 13, 2020 -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn.
- 05/13/2020
|
MediWound to Report First Quarter —…—… Financial Results and Host a Conference Call and ...
|
MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
- MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/12/2020
|
Sargent Investment Group, LLC Buys Iron Mountain Inc, LivePerson Inc, Visa Inc, Sells Universal ...
|
MediWound Announces Distributin Agreements For NexoBrid
|
MediWound Strengthens its NexoBrid European Presence with Additional Distribution Agreements
- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn and wound management, today announced the expansion of its NexoBrid® European presence with distribution agreements granting GENFA MEDICA SA, its distributer in Russia, Ukraine and the Baltic countries, the exclusive right to market and distribute NexoBrid in France and Switzerland and Specialty Therapeutics PC the exclusive right to market and distribute NexoBrid in Greece, Bulgaria, Malta and Cyprus. NexoBrid, currently approved in the European Union and other international markets, is a topically-administered biologic product that removes eschar in patients with deep partial and full-thickness thermal burns.
- 05/04/2020
|
MediWound Strengthens its NexoBrid European Presence with Additional Distribution Agreements
|
MediWound Ltd.'s (NASDAQ:MDWD) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
- It is hard to get excited after looking at MediWound's (NASDAQ:MDWD) recent performance, when its stock has declined...
- 05/02/2020
|
MediWound Strengthens Board of Directors
- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the appointments of Mr. Samuel Moed and Mr. David Fox to its Board of Directors to serve until the 2020 annual meeting of shareholders
- 04/27/2020
|
MediWound Strengthens Board of Directors
|
Vericel to Report First-Quarter 2020 Financial Results on May 5, 2020
- CAMBRIDGE, Mass., April 22, 2020 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the.
- 04/22/2020
|
Vericel Announces Change to a Virtual Meeting Format For 2020 Annual Meeting of Shareholders
- Vericel Corporation (VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that as a result of the COVID-19 pandemic, to support the health and well-being of our employees and shareholders, and to comply with state stay-at-home orders, including the
- 04/10/2020
|
Vericel to Present at the 19th Annual Needham Healthcare Conference on Tuesday, April 14, 2020
- CAMBRIDGE, Mass., April 08, 2020 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that.
- 04/08/2020
|
The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2)BELLUS Health Inc (NASDAQ: BLU)Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 2) * BIOLASE Inc (NASDAQ: BIOL) * BioNano Genomics Inc (NASDAQ
- 04/03/2020
|
The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs April 2)
BELLUS Health Inc (NASDAQ:...
- 04/03/2020
|
Vericel Provides Business and Financial Updates
- First Quarter Preliminary Unaudited Product Revenues Increased Approximately 21% Over First Quarter 2019 Full Year 2020 Financial Guidance Withdrawn Due to Uncertainty.
- 04/02/2020
|
Gone To Pot
- Here are a few marijuana stocks to see how
- 03/31/2020
|
|
|
MediWound Provides Corporate Update Related to COVID-19 Pandemic
- MediWound Ltd. (MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today provided an update on certain impacts of the COVID-19 pandemic on its business operations and clinical programs. At the same time, the Company is working to ensure that healthcare providers and patients have uninterrupted access to our commercial and products under development. The Company has instituted a global remote work policy and is now leveraging virtual tools and digital communication technologies to continue important interactions with its employees, healthcare professionals, patients and other stakeholders.
- 03/30/2020
|
MediWound Provides Corporate Update Related to COVID-–9 Pandemic
|
108 Biggest Movers From Yesterday
- Gainers
Cypress Semiconductor Corporation (NASDAQ: CY) shares jumped 48.9% to close at $22.75 on Tuesday after the company received clearance from the Committee on Foreign...
- 03/11/2020
|
82 Stocks Moving In Tuesday's Mid-Day Session
- Gainers
Cypress Semiconductor Corporation (NASDAQ: CY) climbed 45.8% to $22.28 after the company received clearance from the Committee on Foreign Investment in the United States...
- 03/10/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Enzo Biochem, Inc. (NYSE: ENZ ) Centogene NV (NASDAQ: CNTG ) Inovio Pharmaceuticals Inc (NASDAQ: INO ) Spherix Inc (NASDAQ: SPEX ) ( added to Friday's advance on clinching an option agreement for coronavirus treatment) Down In The Dumps (Biotech stocks that hit 52-week lows March 9.) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc. (NASDAQ: AKRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc.
- 03/10/2020
|
Edited Transcript of MDWD earnings conference call or presentation 25-Feb-20 1:30pm GMT
- Q4 2019 Mediwound Ltd Earnings Call
- 03/10/2020
|
Edited Transcript of VCEL earnings conference call or presentation 25-Feb-20 1:30pm GMT
- Q4 2019 Vericel Corp Earnings Call
- 03/05/2020
|
BARDA Upsizes its Contract with MediWound Awarding an Additional $5.5 Million for Emergency Readiness for NexoBrid Deployment
- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has expanded its awarded contract with MediWound providing supplemental funding of $5.5 million to support emergency readiness for NexoBrid deployment upon request of use of NexoBrid in mass casualty situation.
- 03/03/2020
|
BARDA Upsizes its Contract with MediWound Awarding an Additional $5. ...
|
140 Biggest Movers From Friday
|
MediWound to Present at Cowen and Company 40th Annual Healthcare Conference
- YAVNE, Israel, Feb. 28, 2020 -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn.
- 02/28/2020
|
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on Feb. 27)
Global Cord Blood Corp (...
- 02/28/2020
|
MediWound to Present at Cowen and Company 4…th Annual Healthcare Conference
|
The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy
- The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
- 02/27/2020
|
Organogenesis: Undervalued And Promising Investment Opportunity For 2020
- Puraply is a key growth driver of Organogenesis’ advanced wound care business. There are multiple short-term, mid-term, and long-term growth catalysts for the c
- 02/27/2020
|
Stocks That Hit 52-Week Lows On Thursday
|
Vericel Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Full-Year 2020 Financial Guidance
- Full Year 2019 Product Revenues of $117.9 Million Increased 30% Over 2018 Record Quarterly Revenue and Profit in the Fourth Quarter Conference Call Today at.
- 02/25/2020
|
MediWound Reports Fourth Quarter and Full-Year 2019 Financial Results
- Generated total full-year 2019 revenues of $31.8 million, driven primarily by Vericel license payment and development services to BARDA Initiated U.S. Phase 2 adaptive design.
- 02/25/2020
|
MediWound Q4 EPS $(0.13) Misses $(0.1) Estimate, Sales $5.442M Beat $4.08M Estimate
|
Vericel to Present at the 40th Annual Cowen Healthcare Conference on Monday, March 2, 2020
- CAMBRIDGE, Mass., Feb. 24, 2020 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that.
- 02/24/2020
|
MediWound to Report Fourth Quarter & Fiscal 2019 Financial Results and Host a Conference Call and Webcast on February 25, 2020
- YAVNE, Israel, Feb. 18, 2020 -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn.
- 02/18/2020
|
MediWound Expands its Distribution Agreement with GENFA MEDICA SA to Market NexoBrid in Ukraine and the Baltic States
- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the expansion of its agreement with GENFA MEDICA SA, granting it the exclusive right to market and distribute NexoBrid® in Ukraine, Lithuania, Latvia and Estonia adding to its current rights to distribute NexoBrid in Russia.
- 01/13/2020
|
MediWound Expands its Distribution Agreement with GENFA MEDICA SA to Market NexoBrid in Ukraine and the Baltic States
|
BARDA Initiates the Procurement of NexoBrid for Emergency Response
- MediWound Ltd. (MDWD) and its U.S. commercial partner Vericel Corporation (VCEL) today announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) within the Assistant Secretary for Preparedness and Response (ASPR), a part of the U.S. Department of Health and Human Services (HHS), has begun procuring NexoBrid® for emergency stockpile as part of the HHS mission to build national preparedness for public health medical emergencies. BARDA purchased inventory will be managed by MediWound under vendor managed inventory. The initial BARDA procurement is valued at $16.5 million, with the first delivery of NexoBrid expected by the end of the first quarter of 2020 and additional deliveries occurring over the subsequent five quarters.
- 01/06/2020
|
MediWound and Vericel's NexoBrid Receives $16.5M of Orders from the US Biomedical Advanced Research and Development Authority for Emergency Stockpiling
|
If You Had Bought MediWound (NASDAQ:MDWD) Stock Five Years Ago, You'd Be Sitting On A 57% Loss, Today
- Statistically speaking, long term investing is a profitable endeavour. But unfortunately, some companies simply don't...
- 01/03/2020
|
MediWound Announces New Distribution Agreement In Australia, New Zealand And Singapore With Balance Medical
|
MediWound Initiates US Phase 2 Adaptive Design Study of EscharEx for Treatment of Venous Leg Ulcers
|
MediWound Q3 EPS $(0.11) Beats $(0.15) Estimate, Sales $5.14M Beat $2.08M Estimate
|
Earnings Preview: MediWound (MDWD) Q3 Earnings Expected to Decline
|
Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for
|
Vericel Analyst Projects Wound Care Product Sales Will Grow Fivefold By 2025
- Vericel Corp (NASDAQ: VCEL ), a commercial-stage company that specializes in advanced cell therapies for treating patients with knee cartilage defects and severe burn wounds, is investment-worthy, according to H.C. Wainwright. The Analyst Analyst Swayampakula Ramakanth initiated coverage of Vericel with a Buy rating and $19 price target. The Thesis Vericel is likely to see nearly a fivefold increase in sales from two of its innovative tissue-repairing cell therapies — MACI and Epicel — and NaxoBrid, a partnered product, Ramakanth said in a Wednesday initiation note. (See his track record here. ) The analyst estimates revenues from the three products will grow from $116 million in 2019 to $533 million by 2025. MACI, a cell therapy approved for treating knee cartilage defects, is a … Full story available on Benzinga.com
- 10/09/2019
|
Vericel And MediWound Announce Initiation Of US NexoBrid Expanded Access Treatment Protocol
|
MediWound Ltd. (MDWD) CEO Sharon Malka on Q2 2019 Results - Earnings Call Transcript
|
MediWound Q2 EPS $(0.12) Misses $(0.03) Estimate, Sales $20.7M Do Not Compare to $4.45M Estimate
|
70 Biggest Movers From Yesterday
|
H.C. Wainwright Initiates Coverage On MediWound with Buy Rating, Announces $5.5 Price Target
|
Stocks That Set New 52-Week Lows Friday Morning
|
Stocks that Reached Yearly Lows Thursday Morning
|
42 Stocks Moving In Wednesday's Pre-Market Session
|
Will MediWound (MDWD) Report Negative Q2 Earnings? What You Should Know
|
64 Biggest Movers From Yesterday
|
50 Biggest Movers From Yesterday
|
MediWound Launches EscharEx US Clinical Development Program
|
41 Stocks Moving In Friday's Mid-Day Session
|
60 Biggest Movers From Yesterday
|
40 Stocks Moving In Monday's Mid-Day Session
|
The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut
|
MediWound Appoints Mr. Boaz Gur-Lavie As CFO
|
Target Acquired: The NexoBrid Acquisition And Its Implications For Vericel
|
MediWound Receives Marketing Authorization For NexoBrid From Peru's Ministry Of Health
|
MediWound Q1 EPS $(0.15) Misses $(0.13) Estimate, Sales $461K Miss $560K Estimate
|
72 Biggest Movers From Yesterday
|
MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid in N. America; MediWound to Receive Upfront Payment of $17.5M, $7.5M on U.S. BLA Approval, Up to $125M in Sales Milestones
|
Will MediWound (MDWD) Report Negative Q1 Earnings? What You Should Know
|
MediWound Announces a $125M Share, Warrant, Debt Offering and 11.24M Share Offering by Selling Shareholders
|
MediWound Shares Resume Trade Following Circuit Breaker, Now Up 15%
|
35 Stocks Moving In Friday's Pre-Market Session
|
Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Wed., Jan. 23, 2019
|
MediWound Reports Phase 3 Study Of NexoBrid Met Primary And All Secondary Endpoints With Statistically Significant Results Compared With Control Group
|
MediWound Q3 EPS $(0.11) Up From $(0.16) YoY, Sales $900K Miss $1.11M Estimate
|
Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for
|
MediWound Announces a Contract With $12M of Funding to Support R&D, Options for Up to $31M of Additional Funding
|
MediWound Announces That Its NexoBrid Received Marketing Authorization Form Russia's Ministry Of Health, Commercial Launch Is Expected In The First Half Of 2019
|
MediWound Ltd. (MDWD) CEO Gal Cohen on Q2 2018 Results - Earnings Call Transcript
|
MediWound Q2 EPS $(0.32) Misses $(0.20) Estimate, Sales $1.551M Beat $980K Estimate
|
MediWound Reports Expansion Of NexoBrid Phase 3 Children Innovation Debridement Study To US Burn Centers
|
MediWound Completes Enrollment In U.S. Phase 3 DETECT Study For NexoBrid Topical Burn Treatment; Topline Data Expected Around Year End 2018
|
NexoBrid Receives Marketing Authorization From South Korea's Ministry of Health
|
MediWound Announces FDA Clears Development Pathway for NexoBrid
|
MediWound's (MDWD) CEO Gal Cohen on Q1 2018 Results - Earnings Call Transcript
|
MediWound Q1 EPS $(0.17) Misses $(0.16) Estimate, Sales $520K Miss $580K Estimate
|
33 Biggest Movers From Yesterday
|
28 Stocks Moving In Tuesday's Mid-Day Session
|
MediWound Reports Q4 EPS $(0.09) Beats $(0.17) Est., Sales $530K Misses $630K Est.
|
MediWound (MDWD) Presents At 38th Annual Cowen and Company Healthcare Conference - Slideshow
|
MediWound: Doubling Sales Even Before Likely FDA Approval
|
MediWound Reports Q3 EPS $(0.90) vs $(0.78) In Prior Year Period, Sales $1.96M vs $790K Est.
|
Tel Aviv District Court Ordered MediWound to Purchase Approximately $–. ...
|
MediWound to Host Third Quarter —…–7 Financial Results Conference Call on November –6, ...
|
MediWound Announces Exercise of Underwritersâ Option to Purchase Additional Shares
|
MediWound Names Stephen Wills Chair
|
Cowen & Co. Initiates Coverage On MediWound Ltd. - Ordinary Shares with Outperform Rating, Announces $9.00 Price Target
|
Mid-Afternoon Market Update: Crude Oil Down Over 1%; Synchronoss Technologies Shares Slide
|
MediWound Announces Shelf Offering Common Stock, No Size Disclosed
|
MediWound Successfully Completes Second Cohort of EscharEx Phase 2 Study, Says No Related Systemic Adverse Events Were Reported And That Adverse Events Related TO Local Application Were Mild To Moderate, Reversible and Resolved
|
MediWound Reports Q2 EPS $(0.40) vs $(0.20) Est., Sales $1.227M vs $740K Est.
|
MediWound to Host Second Quarter —…–7 Financial Results Conference Call on August ', ...
|
MediWound Reports Upsizing Of BARDA Contract Commitment Funds From $24M To ~$56M
|
BARDA Gives Notice of Intent to Exercise First Contract Option to Further Fund MediWoundâs ...
|
Independent Study in Germany Shows NexoBrid® Reduces Average Burn Treatment Costs by nearly ...
|
Poster Presentation Highlighting NexoBrid® Awarded âœBest Posterâ at the 5—nd ...
|
MediWound Q1 EPS $(0.20) vs $(0.17) Est, Sales $540K vs $630K Est
|
MediWound to Host First Quarter —…–7 Financial Results Conference Call on May 8, ...
|
Mediwound (MDWD) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow
|
MediWound Announces Conference Call and Webcast of âœMeet the Expertsâ Panel ...
|
MediWoundâs NexoBrid® and EscharEx® to be Highlighted in Presentations at the ...
|
MediWound to Present at the Oppenheimer —7th Annual Healthcare Conference
|
MediWound Q4 EPS $(0.09) vs $(0.25) Est, Revenue $430K vs $730K Est
|
MediWound Says Results from NexoBrid Phase 2 Pharmacokinetic Clinical Study Support Treatment of Severe Burns Covering up to 30% of Total Body Surface Area
|
MediWound gets green light in Europe to include burn patients as young as one year old in late-stage debridement study
|
